A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

Haematologica

Volumn 102, Issue 1, 2017, Pages 94-102

  Gupta, Vikas ^a   Mesa, Ruben A ^b   Deininger, Michael W N ^c   Rivera, Candido E ^d   Sirhan, Shireen ^e   Brachmann, Carrie Baker ^f   Collins, Helen ^f   Kawashima, Jun ^f   Xin, Yan ^f   Verstovsek, Srdan ^g  

^a UNIVERSITY OF TORONTO   (Canada)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d MAYO CLINIC   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f GILEAD SCIENCES   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MOMELOTINIB; SOMATOMEDIN BINDING PROTEIN 1; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR; VASCULOTROPIN A; BENZAMIDE DERIVATIVE; BIOLOGICAL MARKER; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CYTOKINE RELEASE SYNDROME; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERANCE; ERYTHROCYTE TRANSFUSION; FEMALE; GENE MUTATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PALPATION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PHENOTYPE; PRIMARY MYELOFIBROSIS; RETREATMENT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BENZAMIDES; BIOMARKERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; PHENOTYPE; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETREATMENT; TREATMENT OUTCOME;

EID: 85008414144     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.148924     Document Type: Article

References (15)

1. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
2. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
3. Höfener M, Pachl F, Kuster B, Sewald N. Inhibitor-based affinity probes for the investigation of JAK signaling pathways. Proteomics. 2015;15(17):3066-3074.
4. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27(6):1322-1327.
5. Pardanani A, Gotlib J, Gupta V, et al. Update on the long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Blood. 2013;122(21):108.
6. Xin Y, Shao L, Jun S, et al. The relative bioavailability, food effect and drug interaction with omeprazole of momelotinib (GS- 0387, CYT387) tablet formulation in healthy subjects. Presented at: American Association of Pharmaceutical Scientists; November 2-6, 2014; San Diego, CA. Abstract M1320.
7. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097.
8. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
9. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108(5): 1497-1503.
10. Verstovsek S, Hoffman R, Mascarenhas J, et al. A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leukemia Res. 2015; 39(2):157-163.
11. Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015;125(17):2649-2655.
12. Abdelrahman RA, Begna KH, Al-Kali A, et al. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br J Haematol. 2015;169(1):77-80.
13. Verstovsek S, Tam CS, Wadleigh M, et al. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014;38(3):316-322.
14. Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1(5):643-651.
15. Asshoff M, Warr M, Haschka D, et al. The Jak1/Jak2 inhibitor momelotinib inhibits Alk2, decreases hepcidin production and ameliorates anemia of chronic disease (ACD) in rodents. Blood. 2015;126 (23):538.